Published date: Feb 03 2020

Journal Title: Journal of Ophthalmic and Vision Research

Issue title: January–March 2020, Volume 15, Issue 1

Pages: 4–6

DOI: 10.18502/jovr.v15i1.5971

Ramin Tadayoni

This is an Editorial and does not have an abstract.

1. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991;98:823–833.

2. Fluorescein angiographic risk factors for progression of diabetic retinopathy. ETDRS report number 13. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991;98:834–840.

3. Ip MS, Domalpally A, Sun JK, Ehrlich JS. Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy. Ophthalmology 2015;122:367–374.

4. Writing committee for the Diabetic Retinopathy Clinical Research Network, Gross JG, Glassman AR, Jampol LM, Inusah S, Aiello LP, et al. Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. JAMA 2015;314:2137–2146.

5. Wubben TJ, Johnson MW; Anti-VEGF Treatment Interruption Study Group. Anti-VEGF therapy for diabetic retinopathy: consequences of inadvertent treatment interruptions. Am J Ophthalmol 2019;204:13–18.

6. Bonnin S, Dupas B, Lavia C, Erginay A, Dhundass M, Couturier A, et al. Anti-vascular endothelial growth factor therapy can improve diabetic retinopathy score without change in retinal perfusion. Retina 2019;39:426–434.

7. Couturier A, Rey PA, Erginay A, Lavia C, Bonnin S, Dupas B, et al. Swept-source wide-field OCT-angiography versus ultra-wide-field fluorescein angiography assessments of retinal non-perfusion in diabetic retinopathy and edema treated with anti-VEGF. Accepted for publication in Ophthalmology 2019.